Form 10-Q INOVIO PHARMACEUTICALS, For: Jun 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Aegis Capital Comments on Inovio (INO) Following Q2 Results; Cash Position Remains 'Solid'
August 11, 2014 11:05 AM EDTAegis Capital affirms Inovio Pharmaceuticals (AMEX: INO) at Buy with a target price of $19 following Q2 results and update released earlier Monday.
Analyst Ram Selvaraju commented, This morning, Inovio reported financial results for the second quarter of 2014. The firm closed the... More
Inovio Pharmaceuticals (INO) Posts Narrower than Expected Q2 Loss of 18c/Share
August 11, 2014 9:17 AM EDTInovio Pharmaceuticals, Inc. (AMEX: INO) reported Q2 EPS of ($0.18), $0.01 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $3.8 million versus the consensus estimate of $1.8 million.
Dr. J. Joseph Kim, President and CEO, said, "Our second quarter marked a historical... More
